Not Signed In -
Warts, Genital |
Anal Warts |
Clinical Trial: Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of an Investigational Quadrivalent Vaccine
This study is no longer recruiting patients.
|
Purpose
The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Cervical Cancer Genital Warts | Vaccine: Investigational Vaccine | Phase II Phase III |
MedlinePlus related topics: Cervical Cancer; HPV; Sexually Transmitted Diseases
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Eligibility
Ages Eligible for Study: 16 Years - 23 Years, Genders Eligible for Study: Female
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Female with an intact uterus with lifetime history of 0-4 sexual partners
Exclusion Criteria:
- Prior Human Papillomavirus Vaccine (HPV) vaccination;
- Prior abnormal paps;
- Prior history of genital warts
Location Information
Pennsylvania
Call for Information, Horsham, Pennsylvania, 19044, United States
More Information
Study ID Numbers: 2004_080
Record last reviewed: September 2004
Last Updated: October 13, 2004
Record first received: September 22, 2004
ClinicalTrials.gov Identifier: NCT00092482
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: September 2004
Last Updated: October 13, 2004
Record first received: September 22, 2004
ClinicalTrials.gov Identifier: NCT00092482
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
